Associated Papers
Paired tumor-normal sequencing provides insights into the CDKN2A-associated tumor spectrum.
Breen KE et al.
Npj Precision Oncology, 2025
Proteogenomic Profiling of Treatment-Naïve Metastatic Malignant Melanoma.
Kuras M et al.
Cancers, 2025
Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC).
Richards CE et al.
International Journal of Molecular Sciences, 2023
Systematic review and meta-analysis of genomic alterations in acral melanoma.
Broit N et al.
Pigment Cell & Melanoma Research, 2022
The Human Melanoma Proteome Atlas-Complementing the melanoma transcriptome.
Betancourt LH et al.
Clinical and Translational Medicine, 2021
Mutation profile and immunoscore signature in thymic carcinomas: An exploratory study and review of the literature.
Asselta R et al.
Thoracic Cancer, 2021
Identification of Circulating Genomic and Metabolic Biomarkers in Intrahepatic Cholangiocarcinoma.
Winter H et al.
Cancers, 2019
Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06).
Lee SJ et al.
The Oncologist, 2015
Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapy.
Heydt C et al.
Bmc Cancer, 2015
microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome.
Akçakaya P et al.
British Journal of Cancer, 2014
C-kit expression of melanocytic neoplasm and association with clinicopathological parameters and anatomic locations in Chinese people.
Lin YC et al.
The American Journal of Dermatopathology, 2013
Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.
Griewank KG et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2013
Assessment of computational methods for predicting the effects of missense mutations in human cancers.
Gnad F et al.
Bmc Genomics, 2013
Fresh surgical specimens yield breast stem/progenitor cells and reveal their oncogenic abnormalities.
Pommier SJ et al.
Annals of Surgical Oncology, 2012
Lack of correlation between immunohistochemical expression of CKIT and KIT mutations in atypical acral nevi.
Park E et al.
The American Journal of Dermatopathology, 2012
Anorectal melanoma with a KIT-activating mutation, which is a target for tyrosine kinase inhibitor.
Itoh M et al.
International Journal of Clinical Oncology, 2011
Large-scale analysis of KIT aberrations in Chinese patients with melanoma.
Kong Y et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011
V559A and N822I double KIT mutant melanoma with predictable response to imatinib?
McDonnell K et al.
Pigment Cell & Melanoma Research, 2011
Prognostic relevance of KIT and PDGFRA mutations in gastrointestinal stromal tumors.
Braggio E et al.
Anticancer Research, 2010
Mutations of the KIT gene and loss of heterozygosity of the PTEN region in a primary malignant melanoma arising from a mature cystic teratoma of the ovary.
Tate G et al.
Cancer Genetics and Cytogenetics, 2009
KIT gene mutations and copy number in melanoma subtypes.
Beadling C et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2008